| Q36529534 | 92-kD type IV collagenase mediates invasion of human cytotrophoblasts |
| Q40510102 | A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene |
| Q28507163 | A functional overlap of plasminogen and MMPs regulates vascularization during placental development |
| Q30423035 | A gene for a low density lipoprotein receptor-related protein in the nematode Caenorhabditis elegans |
| Q33907027 | A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. |
| Q24555708 | A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene |
| Q33924144 | A plasminogen activator is induced during goldfish optic nerve regeneration |
| Q24564642 | A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state |
| Q74619482 | Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation |
| Q73047422 | Angiogenin plasma levels during pregnancy |
| Q40735093 | Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation |
| Q59004532 | Better reception for urokinase |
| Q24647068 | CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth |
| Q41619434 | Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety. |
| Q41963069 | Changes in cell surface and intracellular glycoproteins of trophoblastic giant cells during mouse placentation |
| Q48045246 | Characterization of UEF-4, a DNA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer |
| Q24564351 | Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor |
| Q50515268 | Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling. |
| Q37340572 | Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein. |
| Q72084243 | Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells |
| Q52243464 | Developmental transition in plasticity properties of differentiating astrocytes: age-related biochemical profile of plasminogen activators in astroglial cultures. |
| Q73289107 | Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system |
| Q34202408 | Differential protease expression by cutaneous squamous and basal cell carcinomas |
| Q35629711 | EGF increases expression and activity of PAs in preimplantation rat embryos and their implantation rate |
| Q51193931 | Effect of transforming growth factor-beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts. |
| Q61453347 | Effects of Progesterone and 17β-Estradiol under Presence or Absence of FBS on Plasminogen Activators Activity in Porcine Uterine Epithelial Cells |
| Q44068270 | Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-1alpha treated articular chondrocytes. |
| Q26865616 | Epidermal growth factor, from gene organization to bedside |
| Q77974196 | Evaluation of extracellular matrix proteins and tissue inhibitor of matrix metalloproteinases-2 on bovine inner cell mass outgrowth in vitro |
| Q35833539 | Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis |
| Q35750477 | Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis |
| Q52178437 | Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. |
| Q41349227 | Expression of osteopontin in a macrophage cell line and in transgenic mice with pulmonary fibrosis resulting from the lung expression of a tumor necrosis factor-alpha transgene |
| Q24792833 | Expression of plasminogen activators in preimplantation rat embryos developed in vivo and in vitro |
| Q73407055 | Expression of stromelysin-3 in the human placenta and placental bed |
| Q35833094 | Expression of tumor necrosis factor-alpha and its mRNA in the endometrial mucosa during the menstrual cycle. |
| Q34170437 | Extracellular proteolysis in the adult murine brain |
| Q52508262 | Gastrulation in the Sea Urchin, Strongylocentrotus purpuratus, Is Disrupted by the Small Laminin Peptides YIGSR and IKVAV |
| Q33832324 | Genes and signals regulating murine trophoblast cell development |
| Q40489756 | Hormonal regulation of the fibrinolytic components in the ovary |
| Q73692252 | Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity |
| Q42462623 | Immunohistochemical identification of the receptor for urokinase plasminogen activator associated with fibrin deposition in normal and ectopic human placenta |
| Q59663108 | Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites |
| Q35172771 | Impact of Endothelial Activation on Fibrinolysis and Local Proteolysis in Tissue Repair |
| Q71031929 | Impaired wound healing in mice with a disrupted plasminogen gene |
| Q35225967 | Improved blastocyst development of single cow OPU-derived presumptive zygotes by group culture with agarose-embedded helper embryos |
| Q37293011 | In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis |
| Q54038662 | Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). |
| Q36308560 | Influence of transforming growth factor-alpha on expression of matrix metalloproteinase-2, matrix metalloproteinase-9, and epidermal growth factor receptor gene in the mouse blastocysts |
| Q36673559 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? |
| Q72378611 | LPS induces major changes in the extracellular proteolytic balance in the murine kidney |
| Q38308888 | Large-scale transcriptional analysis of bovine embryo biopsies in relation to pregnancy success after transfer to recipients. |
| Q63915864 | Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor |
| Q89560302 | Localization of urokinase-type and tissue-type plasminogen activator mRNA during organogenesis in the mouse |
| Q52198955 | Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. |
| Q36741529 | Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells |
| Q34611765 | MMP9 is protective against lethal inflammatory mass lesions in the mouse colon. |
| Q38292156 | Maternal obesity is associated with ovarian inflammation and upregulation of early growth response factor 1. |
| Q39948157 | Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces |
| Q50800694 | Matrix metalloproteinase expression and activity in trophoblast-decidual tissues at organogenesis in CF-1 mouse. |
| Q34126544 | Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems |
| Q41513276 | Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. |
| Q46478789 | Metalloproteinases mediate extracellular matrix degradation by cells from mouse blastocyst outgrowths |
| Q73646242 | Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice |
| Q37424686 | Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. |
| Q33768031 | New insights into the role of Plg-RKT in macrophage recruitment |
| Q41720951 | Normal ultrastructure of the kidney and lower urinary tract |
| Q40860158 | Oct-1 specifically binds the UEF4 site of the human AP1-regulated urokinase enhancer |
| Q44456465 | Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells |
| Q38296690 | Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells |
| Q33680725 | Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators |
| Q38704015 | Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors |
| Q59069678 | Physiological consequences of loss of plasminogen activator gene function in mice |
| Q37093084 | Plasminogen Activators in Endometrial Physiology and Embryo Implantation: A Review |
| Q40444813 | Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences |
| Q41100535 | Plasminogen activation on tumor cell surface and its involvement in human leukemia. |
| Q36457877 | Plasminogen activator-dependent pericellular proteolysis |
| Q72370854 | Plasminogen activators in ectopic and uterine endometrium |
| Q38361491 | Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters |
| Q51557069 | Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). |
| Q41206436 | Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. |
| Q40249142 | Reciprocal upregulation of urokinase plasminogen activator and its inhibitor, PAI-2, by Borrelia burgdorferi affects bacterial penetration and host-inflammatory response |
| Q34736190 | Regulation and role of urokinase plasminogen activator in vascular remodelling |
| Q40870212 | Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution |
| Q35142158 | Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9 |
| Q59081120 | Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis |
| Q36224071 | Role of the extracellular matrix protein thrombospondin in the early development of the mouse embryo |
| Q46463604 | Serine protease HtrA1 is developmentally regulated in trophoblast and uterine decidual cells during placental formation in the mouse |
| Q33185570 | Serine protease inhibitor-E2 (SERPINE2) is differentially expressed in granulosa cells of dominant follicle in cattle |
| Q35819933 | Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney |
| Q71575223 | Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney |
| Q33962794 | Stromelysin-3 in the biology of the normal and neoplastic mammary gland. |
| Q34164078 | Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells |
| Q67485362 | The PA‐Plasmin System during Murine Embryogenesis |
| Q37355545 | The kidney is a major site of alpha(2)-antiplasmin production |
| Q40934291 | The plasminogen activation system in tumour invasion and metastasis |
| Q74296167 | The plasminogen activator system in women with polycystic ovary syndrome |
| Q34202297 | The plasminogen activator/plasmin system |
| Q35477781 | The plasminogen-plasmin system in malignancy |
| Q24678932 | The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes |
| Q34545851 | The role of megalin (LRP-2/Gp330) during development |
| Q40406446 | The urokinase/urokinase-receptor system and cancer invasion |
| Q73502113 | The use of RNA probes for the analysis of gene expression |
| Q72298241 | Treatment with gonadotropins impaired implantation and fetal development in mice |
| Q36229956 | Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions |
| Q41877722 | Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract |
| Q36232769 | Upregulation of urokinase receptor expression on migrating endothelial cells |
| Q77162228 | Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer |
| Q28566670 | Urokinase redistribution from the secreted to the cell-bound fraction in granulosa cells of rat preovulatory follicles |